Biotech exec Samuel Waksal argues for a pay-for-results system
(Newser) -
Medical costs, and especially drug costs, are scandalously high in the US, but just capping them isn't the answer, biotech exec Samuel Waksal writes in the New York Times . "Individuals and insurance companies should be willing to pay—and pay a lot—for drugs when they work,"...